FDA Approves Landmark Durvalumab and Padcev Immunotherapy Combination for Muscle-Invasive Bladder Cancer

SILVER SPRING, Md. — Delivering a transformative breakthrough for tens of thousands of oncology patients facing aggressive urological malignancies, the Food and Drug Administration (FDA) on Friday formally approved the combination of durvalumab (marketed as Imfinzi) and enfortumab vedotin-ejfv (Padcev) for the treatment of muscle-invasive bladder cancer (MIBC).

The landmark regulatory clearance authorizes the dual-drug regimen as neoadjuvant therapy prior to radical cystectomy surgery, followed by maintenance single-agent durvalumab as adjuvant immunotherapy for adult patients who are medically ineligible for, or decline, standard cisplatin-based chemotherapy. Cisplatin eligibility has historically been a severe barrier for elderly bladder cancer patients suffering from renal impairment, peripheral neuropathy, or heart failure.

The FDA's decision was anchored by robust clinical evidence generated from the international Phase 3 VOLGA clinical trial. The randomized multi-center study demonstrated statistically significant and clinically meaningful improvements across both primary endpoints, showing dramatic reductions in cancer recurrence rates and a substantial increase in overall survival compared to standard surgical resection alone. Pathological complete response rates—meaning no residual malignant cells were detected in excised tissue—surpassed previous benchmarks.

'For decades, muscle-invasive bladder cancer patients unable to tolerate harsh cisplatin chemotherapy faced grim prognostic outcomes and limited therapeutic options before surgery,' said a lead investigator from Memorial Sloan Kettering Cancer Center. 'This dual targeted antibody-drug conjugate and checkpoint inhibitor combination fundamentally shifts clinical practice, offering a potent, life-extending therapeutic bridge that eliminates tumors while preserving patient functional capacity.'

The approval caps an intensely active regulatory week at the FDA, which also granted 510(k) clearance to an AI-assisted diagnostic software platform designed to identify cerebral aneurysms on CT scans, and mandated class-wide safety warnings across GLP-1 weight-loss medications. Clinical oncologists across the country commended the bladder cancer approval, forecasting immediate adoption across comprehensive cancer centers nationwide.